Articles by tag: ovarian-cancer

FDA Fast Track for ADC ZW191 against resistant ovarian cancer

ADC ZW191 received Fast Track status from FDA for platinum-resistant ovarian cancer. ORR 64%, works with low FRα expression. Learn about the breakthrough and risks.

Triple therapy for ovarian cancer: breakthrough or myth 2026?

Analyzing triple therapy for ovarian cancer with a 40% increase in survival. Current data, alternatives, and forecasts for patients and doctors. Read.

CAR-T therapy for ovarian cancer: lira-cel and 28 months of life

Updated Phase I data: CAR-T lira-cel showed 28-month survival in ovarian cancer. Learn why this is a breakthrough in solid tumor treatment.